pharmaphorum May 23, 2024
Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at around $600 million.
If completed, the acquisition will make Mirus Bio part of Merck’s US and Canadian life sciences division MilliporeSigma, which provides a wide range of products used in the production of CGTs, as well as operating as a contract development and manufacturing organisation (CDMO).
Life sciences is a major arm of Merck’s business – contributing around €9.3 billion out of the group’s total net sales of €21 billion last year – but has been under pressure since the end of the pandemic as a result of a steep fall-off...
Today's Sponsors
Today's Sponsor